<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957839</url>
  </required_header>
  <id_info>
    <org_study_id>Aşıcıoğlu-08</org_study_id>
    <secondary_id>OA8</secondary_id>
    <nct_id>NCT01957839</nct_id>
  </id_info>
  <brief_title>Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Bakirkoy Maternity and Children Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Bakirkoy Maternity and Children Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators examined the hypothesis that hyperprolactinemia may alter uterin,
      endometrial and intraovarian blood flow and may contribute to increased infertility by
      another way.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>th effect of prolactin vascular flow and resistance</measure>
    <time_frame>the effect of prolactin in vascular resistance at 2 weeks after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Adverse Reaction to Other Drugs and Medicines</condition>
  <arm_group>
    <arm_group_label>pretreatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>doppler evaluation at pretreatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>posttreatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doppler evaluatıon in normoprolactinemia women who given cabergoline treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabergoline treatment</intervention_name>
    <description>cabergoline treatment for hyperprolactinemia group</description>
    <arm_group_label>posttreatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who had blood prolactin level higher than 25ng/dl

        Exclusion Criteria:

          -  Pregnancy

          -  Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives,
             antihypertensives

          -  Diseases like pelvic inflammatory disease and systemic hypertension

          -  Women with clinically overt or treated cardiovascular disease

          -  Concurrent illness other than hyperprolactinemia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osman Temizkan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SİSLİ ETFAL TEACHİNG HOSPİTAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sisli Etfal Teaching Hosital</name>
      <address>
        <city>Sisli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010 Jun;95(6):2672-9. doi: 10.1210/jc.2009-2605. Epub 2010 Mar 31.</citation>
    <PMID>20357175</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Bakirkoy Maternity and Children Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Osman Aşıcıoğlu</investigator_full_name>
    <investigator_title>sisli etfal teaching hospital department gynecology and obstetric</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

